Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in 2025.

Various PD-1 and PD-L1 checkpoint inhibitors have been approved by U.S. regulators including blockbuster drugs Keytruda, Imfinzi, and Opdivo to treat different types of cancer. But that hasn’t stopped ...

The month of December 2024 saw a variety of biotech deals take place to advance therapies across different stages in ...

First-in-class drugs are therapies that utilize novel mechanisms of action, offering new approaches to challenging diseases. In 2024, the U.S. Food and Drug Administration (FDA) approved 50 new ...